Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Barbie

Showing results (111-120 of 120) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 120 results.
Nature Cancer|April 26, 2021
EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancerKatherine L Morel, Anjali V Sheahan, Deborah L Burkhart, et al.
Cancer Discovery|March 12, 2021
Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular PlasticityNavin R Mahadevan, Erik H Knelson, Jacquelyn O Wolff, et al.
Cancer Cell|January 15, 2020
Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic PathwayKari J Kurppa, Yao Liu, Ciric To, et al.
Cancer Immunology Research|June 12, 2025
Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor That Unleashes PD-1 Checkpoint and CAR T-Cell ImmunotherapiesMichael Wichroski, Si-Qi Liu, Lauren M Zasadil, et al.
Cancer Discovery|November 5, 2017
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell ActivationJiehui Deng, Eric S Wang, Russell W Jenkins, et al.
Cancer Immunology Research|June 9, 2022
Activation of Tumor-Cell STING Primes NK-Cell TherapyErik H Knelson, Elena V Ivanova, Mubin Tarannum, et al.
Cell|November 3, 2018
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint BlockadeLivnat Jerby-Arnon, Parin Shah, Michael S Cuoco, et al.
Cancer Cell|March 6, 2026
Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancerMarco Campisi, Tatsuya Osaki, Ian Dryg, et al.
Nature|January 12, 2023
Targeting TBK1 to overcome resistance to cancer immunotherapyYi Sun, Or-Yam Revach, Seth Anderson, et al.
Cancer Discovery|November 5, 2017
<i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor SpheroidsRussell W Jenkins, Amir R Aref, Patrick H Lizotte, et al.
Pageof 12

Showing results (111-120 of 120) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 120 results.
Nature Cancer|April 26, 2021
EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancerKatherine L Morel, Anjali V Sheahan, Deborah L Burkhart, et al.
Cancer Discovery|March 12, 2021
Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular PlasticityNavin R Mahadevan, Erik H Knelson, Jacquelyn O Wolff, et al.
Cancer Cell|January 15, 2020
Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic PathwayKari J Kurppa, Yao Liu, Ciric To, et al.
Cancer Immunology Research|June 12, 2025
Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor That Unleashes PD-1 Checkpoint and CAR T-Cell ImmunotherapiesMichael Wichroski, Si-Qi Liu, Lauren M Zasadil, et al.
Cancer Discovery|November 5, 2017
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell ActivationJiehui Deng, Eric S Wang, Russell W Jenkins, et al.
Cancer Immunology Research|June 9, 2022
Activation of Tumor-Cell STING Primes NK-Cell TherapyErik H Knelson, Elena V Ivanova, Mubin Tarannum, et al.
Cell|November 3, 2018
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint BlockadeLivnat Jerby-Arnon, Parin Shah, Michael S Cuoco, et al.
Cancer Cell|March 6, 2026
Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancerMarco Campisi, Tatsuya Osaki, Ian Dryg, et al.
Nature|January 12, 2023
Targeting TBK1 to overcome resistance to cancer immunotherapyYi Sun, Or-Yam Revach, Seth Anderson, et al.
Cancer Discovery|November 5, 2017
<i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor SpheroidsRussell W Jenkins, Amir R Aref, Patrick H Lizotte, et al.
Pageof 12